Publication | Closed Access

Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7′-substituents and initial pharmacokinetic assessments

BiochemistryMedicineAntiviral Drug DevelopmentAntiviral TherapyPharmacotherapyAntiviral DrugFurther OptimizationPharmacologyAntiviral CompoundInitial Pharmacokinetic AssessmentsDrug Discovery